Individualized therapy based on molecular alterations in gynecologic cancer
- Prosjektnummer
- 911717
- Ansvarlig person
- Jone Trovik
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Postdoktorstipend
- Helsekategori
- Cancer, Renal and Urogenital
- Forskningsaktivitet
- 5. Treatment Developement, 6. Treatment Evaluation
Vi har involvert gyncancerpasientforening mhp diskusjon før igansetting av prosjekt der vi selekterer til ulike operasjonsmetoder basert på biomarkører og spesielt fått råd mhp viktigheten av samt hvordan gjennomføre livskvalitetsregistrering
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value.
Br J Cancer 2023 Feb;128(4):647. Epub 2022 des 8
PMID: 36482191
APOBEC3A/B deletion polymorphism and endometrial cancer risk.
Cancer Med 2023 Mar;12(6):6659. Epub 2022 nov 16
PMID: 36394079
MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer.
Insights Imaging 2022 Jan 08;13(1):1. Epub 2022 jan 8
PMID: 35000020
Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study.
Am J Obstet Gynecol 2022 Jan;226(1):90.e1. Epub 2021 aug 13
PMID: 34400137
Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Gynecol Oncol 2021 06;161(3):787-794. Epub 2021 apr 12
PMID: 33858677
Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer.
Cancers (Basel) 2021 Mar 18;13(6). Epub 2021 mar 18
PMID: 33803531
An MRI-Based Radiomic Prognostic Index Predicts Poor Outcome and Specific Genetic Alterations in Endometrial Cancer.
J Clin Med 2021 Feb 02;10(3). Epub 2021 feb 2
PMID: 33540589
Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer.
Gynecol Oncol 2021 02;160(2):396-404. Epub 2020 des 13
PMID: 33317908
Whole-Volume Tumor MRI Radiomics for Prognostic Modeling in Endometrial Cancer.
J Magn Reson Imaging 2021 03;53(3):928-937. Epub 2020 nov 16
PMID: 33200420
Cancer awareness in the general population varies with sex, age and media coverage: A population-based survey with focus on gynecologic cancers.
Eur J Obstet Gynecol Reprod Biol 2021 Jan;256():25-31. Epub 2020 nov 1
PMID: 33161211
Tumour texture features from preoperative CT predict high-risk disease in endometrial cancer.
Clin Radiol 2021 01;76(1):79.e13-79.e20. Epub 2020 sep 14
PMID: 32938538
Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer.
Int J Cancer 2021 01 15;148(2):307-319. Epub 2020 aug 7
PMID: 32851660
A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease.
Br J Cancer 2021 05;124(10):1690-1698. Epub 2021 mar 15
PMID: 33723390
Prognostic Value of the Diversity of Nuclear Chromatin Compartments in Gynaecological Carcinomas.
Cancers (Basel) 2020 Dec 19;12(12). Epub 2020 des 19
PMID: 33352679
Gynaecological fistulae after surgery or radiotherapy.
Tidsskr Nor Laegeforen 2020 Sep 08;140(12). Epub 2020 sep 7
PMID: 32900175
Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study.
PLoS Med 2020 05;17(5):e1003111. Epub 2020 mai 15
PMID: 32413043
Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.
Br J Cancer 2020 03;122(7):1014-1022. Epub 2020 feb 10
PMID: 32037399
Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer.
Eur Radiol 2020 May;30(5):2443-2453. Epub 2020 feb 7
PMID: 32034487
High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer.
Gynecol Oncol 2020 04;157(1):260-267. Epub 2020 jan 21
PMID: 31973911
Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling.
Gynecol Oncol 2020 02;156(2):400-406. Epub 2019 des 6
PMID: 31813586
Poor outcome in hypoxic endometrial carcinoma is related to vascular density.
Br J Cancer 2019 May;120(11):1037-1044. Epub 2019 apr 23
PMID: 31011231
Novel PCDH10-Wnt-MALAT1 regulatory axis in endometrioid endometrial adenocarcinoma.
Hong Kong Med J 2019 Oct;25 Suppl 7(5):17-22.
PMID: 31761765
Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study.
Hum Pathol 2019 Jul;89():90-98. Epub 2019 mai 3
PMID: 31054899
Blood Metabolites Associate with Prognosis in Endometrial Cancer.
Metabolites 2019 Dec 14;9(12). Epub 2019 des 14
PMID: 31847385
Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
Clin Cancer Res 2019 01 01;25(1):334-345. Epub 2018 nov 15
PMID: 30442683
Blood steroids are associated with prognosis and fat distribution in endometrial cancer.
Gynecol Oncol 2019 01;152(1):46-52. Epub 2018 okt 26
PMID: 30554934
Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer.
PLoS One 2019;14(1):e0210585. Epub 2019 jan 15
PMID: 30645608
Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.
Cancer Lett 2018 01 28;413():23-34. Epub 2017 okt 26
PMID: 29107108
HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.
Br J Cancer 2018 02 06;118(3):378-387. Epub 2017 nov 23
PMID: 29169184
Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer.
Acta Radiol 2018 Aug;59(8):1010-1017. Epub 2017 nov 14
PMID: 29137496
Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
Gynecol Oncol 2018 01;148(1):197-203. Epub 2017 okt 31
PMID: 29096882
Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients.
Oncotarget 2017 Dec 12;8(65):109018-109026. Epub 2017 nov 20
PMID: 29312587
Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients.
Oncotarget 2017 Dec 05;8(63):106989-107001. Epub 2017 okt 31
PMID: 29291005
High visceral fat percentage is associated with poor outcome in endometrial cancer.
Oncotarget 2017 Dec 01;8(62):105184-105195. Epub 2017 okt 19
PMID: 29285243
Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers.
Oncotarget 2017 Sep 15;8(40):68530-68541. Epub 2017 jul 31
PMID: 28978135
Type of vascular invasion in association with progress of endometrial cancer.
APMIS 2017 Dec;125(12):1084-1091. Epub 2017 okt 4
PMID: 28975668
Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.
Gynecol Oncol 2017 12;147(3):672-677. Epub 2017 sep 18
PMID: 28927900
In vivo MR spectroscopy predicts high tumor grade in endometrial cancer.
Acta Radiol 2018 Apr;59(4):497-505. Epub 2017 sep 19
PMID: 28927296
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
Sci Rep 2017 Aug 31;7(1):10240. Epub 2017 aug 31
PMID: 28860563
Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study.
PLoS One 2017;12(8):e0182223. Epub 2017 aug 3
PMID: 28771617
Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients.
Br J Cancer 2017 Sep 05;117(6):840-847. Epub 2017 jul 27
PMID: 28751757
Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Clin Cancer Res 2017 Mar 01;23(5):1274-1285.
PMID: 28232476
Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.
Oncotarget 2017 Feb 07;8(6):9696-9707.
PMID: 28039471
Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer.
Cancer Epidemiol Biomarkers Prev 2017 Jan;26(1):61-67. Epub 2016 sep 1
PMID: 27587790
Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer.
Cancer Epidemiol Biomarkers Prev 2016 Nov;25(11):1503-1510. Epub 2016 aug 22
PMID: 27550749
Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer.
Oncotarget 2016 Oct 25;7(43):69844-69856.
PMID: 27634881
L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
Br J Cancer 2016 Sep 06;115(6):716-24. Epub 2016 aug 9
PMID: 27505134
Androgen receptor as potential therapeutic target in metastatic endometrial cancer.
Oncotarget 2016 Aug 02;7(31):49289-49298.
PMID: 27384477
The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.
Nat Genet 2016 Aug;48(8):848-55. Epub 2016 jun 27
PMID: 27348297
Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth.
Sci Rep 2016 May 10;6():25521. Epub 2016 mai 10
PMID: 27160768
Five endometrial cancer risk loci identified through genome-wide association analysis.
Nat Genet 2016 Jun;48(6):667-74. Epub 2016 mai 2
PMID: 27135401
CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer.
Endocr Relat Cancer 2016 Feb;23(2):77-91. Epub 2015 nov 16
PMID: 26574572
Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.
Clin Cancer Res 2016 Jan 15;22(2):513-23. Epub 2015 jul 29
PMID: 26224872
Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1.
Sci Rep 2015;5():17369. Epub 2015 des 1
PMID: 26621817
Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses.
Oncotarget 2015 Nov 24;6(37):39676-91.
PMID: 26485755
Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer.
Endocr Relat Cancer 2015 Oct;22(5):851-61.
PMID: 26330482
ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma.
Oncotarget 2015 Sep 29;6(29):28440-52.
PMID: 26308378
Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
J Nucl Med 2015 Aug;56(8):1191-8. Epub 2015 jun 4
PMID: 26045311
DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer.
Br J Cancer 2015 May 12;112(10):1656-64. Epub 2015 apr 21
PMID: 25897678
Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer.
Oncotarget 2015 Apr 30;6(12):10634-45.
PMID: 25860936
Tumour apparent diffusion coefficient is associated with depth of myometrial invasion and is negatively correlated to tumour volume in endometrial carcinomas.
Clin Radiol 2015 May;70(5):487-94. Epub 2015 jan 30
PMID: 25639620
Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas.
Int J Gynecol Cancer 2015 Mar;25(3):459-66.
PMID: 25628109
Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk.
Hum Genet 2015 Feb;134(2):231-45. Epub 2014 des 9
PMID: 25487306
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
Oncotarget 2015 Jan 20;6(2):1327-39.
PMID: 25415225
Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk.
Hum Mol Genet 2015 Mar 1;24(5):1478-92. Epub 2014 nov 6
PMID: 25378557
Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.
Eur J Cancer 2014 Nov;50(17):3003-10. Epub 2014 sep 30
PMID: 25281525
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer.
Mol Cancer 2014;13():223. Epub 2014 sep 27
PMID: 25261936
A novel wnt regulatory axis in endometrioid endometrial cancer.
Cancer Res 2014 Sep 15;74(18):5103-17. Epub 2014 aug 1
PMID: 25085246
Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.
Gynecol Oncol 2014 Sep;134(3):599-606. Epub 2014 jul 1
PMID: 24995579
High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors.
Br J Cancer 2014 Jul 8;111(1):78-84. Epub 2014 mai 22
PMID: 24853175
Switch in FOXA1 status associates with endometrial cancer progression.
PLoS One 2014;9(5):e98069. Epub 2014 mai 21
PMID: 24849812
Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
Oncotarget 2014 Feb 28;5(4):1052-61.
PMID: 24658009
Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.
PLoS One 2014;9(2):e90141. Epub 2014 feb 25
PMID: 24587245
Growth differentiation factor-15 as biomarker in uterine sarcomas.
Int J Gynecol Cancer 2014 Feb;24(2):252-9.
PMID: 24401984
Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas.
Br J Cancer 2014 Jan 7;110(1):107-14. Epub 2013 okt 31
PMID: 24178757
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Cancer 2014 Feb 15;120(4):603-10. Epub 2013 okt 25
PMID: 24166148
Polymorphisms in inflammation pathway genes and endometrial cancer risk.
Cancer Epidemiol Biomarkers Prev 2013 Feb;22(2):216-23. Epub 2012 des 5
PMID: 23221126
Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence.
Eur Radiol 2013 Oct;23(10):2916-25. Epub 2013 jun 4
PMID: 23732687
Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas.
Gynecol Oncol 2013 Nov;131(2):410-5. Epub 2013 sep 1
PMID: 24004646
Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.
PLoS One 2013;8(2):e54873. Epub 2013 feb 5
PMID: 23393560
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Eur J Cancer 2013 Nov;49(16):3431-41. Epub 2013 aug 8
PMID: 23932335
ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
Mod Pathol 2013 Mar;26(3):428-34. Epub 2012 okt 19
PMID: 23080032
A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis.
Eur J Cancer 2013 Feb;49(3):625-32. Epub 2012 okt 1
PMID: 23036850
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
Clin Cancer Res 2013 May 1;19(9):2331-41. Epub 2013 mar 28
PMID: 23538402
Lack of estrogen receptor-a is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.
Clin Cancer Res 2013 Mar 1;19(5):1094-105. Epub 2013 jan 14
PMID: 23319822
High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated.
PLoS One 2012;7(12):e52795. Epub 2012 des 27
PMID: 23300780
KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
Br J Cancer 2012 Dec;107(12):1997-2004. Epub 2012 okt 25
PMID: 23099803
Markers for individualised therapy in endometrial carcinoma.
Lancet Oncol 2012 Aug;13(8):e353-61.
PMID: 22846840
Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas.
Gynecol Oncol 2012 Sep;126(3):413-8. Epub 2012 mai 15
PMID: 22609110
Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists.
Eur Radiol 2012 Jul;22(7):1601-11. Epub 2012 mar 28
PMID: 22453859
Loss of GPER identifies new targets for therapy among a subgroup of ERa-positive endometrial cancer patients with poor outcome.
Br J Cancer 2012 May;106(10):1682-8. Epub 2012 mar 13
PMID: 22415229
Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective.
Gynecol Oncol 2012 May;125(2):381-7. Epub 2012 feb 1
PMID: 22307064
Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas.
Histopathology 2012 Feb;60(3):516-9. Epub 2011 des 14
PMID: 22168220
Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification.
Gynecol Oncol 2012 Apr;125(1):103-8. Epub 2011 nov 17
PMID: 22100838
- Henrica Maria Johanna Werner Prosjektdeltaker
- Camilla Krakstad Leder av forskningsgruppe
- Jone Trovik Postdoktor
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest